Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emmaus Life SciencesEMMA -0.52% EV-to-EBITDA is -73.54 as of Jul. 19, 2026. The stock has 6 warning signs investors should review. Among 398 Biotechnology companies, Emmaus Life Sciences ranks worse than 251256.03% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Emmaus Life Sciences's enterprise value is $31.99 Mil.
Emmaus Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.44 Mil. Therefore, Emmaus Life Sciences's EV-to-EBITDA for today is -73.54.
The historical rank and industry rank for Emmaus Life Sciences's EV-to-EBITDA or its related term are showing as below:
EMMA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -101.37 Med: -2.33 Max: 70.94
Current: -73.54
During the past 13 years, the highest EV-to-EBITDA of Emmaus Life Sciences was 70.94. The lowest was -101.37. And the median was -2.33.
EMMA's EV-to-EBITDA is ranked worse than 100% of 398
companies
in the Biotechnology industry
Industry Median: 12.205
vs EMMA: -73.54
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Emmaus Life Sciences (OTCPK:EMMA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Emmaus Life Sciences's PE Ratio (TTM) for today is calculated as:
Emmaus Life Sciences's share price for today is $0.0114.
Emmaus Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.130.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Emmaus Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Emmaus Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's EV-to-EBITDA falls into.
Emmaus Life Sciences's current Enterprise Value is $31.99 Mil.
Emmaus Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a EV-to-EBITDA of -73.54 as of Jul. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Emmaus Life Sciences. According to the industry distribution chart, Emmaus Life Sciences ranks #999999 out of 398 companies in the Biotechnology industry.
Is Emmaus Life Sciences' EV-to-EBITDA too high?
Emmaus Life Sciences' current EV-to-EBITDA is -73.54. Based on the distribution chart, Emmaus Life Sciences ranks #999999 out of 398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Emmaus Life Sciences' EV-to-EBITDA compare to PTIX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #999999 out of 398 companies for EV-to-EBITDA. This places Emmaus Life Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 12.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.21, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Emmaus Life Sciences. For the Biotechnology industry, the median EV-to-EBITDA is 12.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current EV-to-EBITDA is -73.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 14% above its estimated fair value. The current EV-to-EBITDA is -73.54. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current EV-to-EBITDA is -73.54 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 
